Based on the findings in this paper, I am extremely excited for this ALP-focused presentation at AHA.

ALP Levels Predict Adverse Cardiovascular Outcomes and Cognitive Impairment in High Risk Patients

https://www.abstractsonline.com/pp8/#!/7891/presentation/26828

The recent paper focused on association of ALP with cardio outcomes. Very excited to hear about associations of ALP with cardio outcomes AND cognitive impairment will be discussed at AHA. Apabetalone and BETonMACE may be the things that put ALP on the map as a risk marker. And if apabetalone in BETonMACE can again show significant reduction of ALP, then we will have a proven drug to modify this risk factor. Note, these are different studies/comparisons than the previously published paper that looked at changes in ALP and eGFR specifically the CKD cohort Phase 2 post-hoc analysis.

BearDownAZ